Smallpox antiviral drug development: satisfying the animal efficacy rule

References

• Moss B. Poxviridae and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds), Raven Press, Ltd., NY, USA, 2849–2884 (2001).
   Google Scholar
• Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol.83(Pt 12), 2915–2931 (2002).
   PubMed Web of Science ®Google Scholar
• Byrd CM, Bolken TC, Hruby DE. The vaccinia virus I7L gene product is the core protein proteinase. J. Virol.76(17), 8973–8976 (2002).
   PubMed Web of Science ®Google Scholar
• Blasco R, Moss B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol.65(11), 5910–5920 (1991).
   PubMed Web of Science ®Google Scholar
• Cudmore S, Cossart P, Griffiths G, Way M. Actin-based motility of vaccinia virus. Nature378(6557), 636–638 (1995).
   PubMed Web of Science ®Google Scholar
• Roper RL, Wolffe EJ, Weisberg A, Moss B. The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J. Virol.72(5), 4192–4204 (1998).
   PubMed Web of Science ®Google Scholar
• Payne LG. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol.50(1), 89–100 (1980).
   PubMed Web of Science ®Google Scholar
• Payne LG, Kristensson K. Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo. J. Gen. Virol.66(Pt 3), 643–646 (1985).
   PubMed Web of Science ®Google Scholar
• McIntosh AA, Smith GL. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J. Virol.70(1), 272–281 (1996).
   PubMed Web of Science ®Google Scholar
• Stern RJ, Thompson JP, Moyer RW. Attenuation of B5R mutants of rabbitpox virus in vivo is related to impaired growth and not an enhanced host inflammatory response. Virology233(1), 118–129 (1997).
   PubMed Web of Science ®Google Scholar
• Zhang WH, Wilcock D, Smith GL. Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence. J. Virol.74(24), 11654–11662 (2000).
   PubMed Web of Science ®Google Scholar
• Boulter EA, Zwartouw HT, Titmuss DH, Maber HB. The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am. J. Epidemiol.94(6), 612–620 (1971).
   PubMed Web of Science ®Google Scholar
• Reeves PM, Bommarius B, Lebeis S et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Med.11(7), 731–739 (2005).
   PubMed Web of Science ®Google Scholar
• Yang G, Pevear DC, Davies MH et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol.79(20), 13139–13149 (2005).
   PubMed Web of Science ®Google Scholar
• Yang H, Kim SK, Kim M et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest.115(2), 379–387 (2005).
   PubMed Web of Science ®Google Scholar
• Vanderplasschen A, Hollinshead M, Smith GL. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol.78(Pt 8), 2041–2048 (1997).
   PubMed Web of Science ®Google Scholar
• Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl Acad. Sci. USA95(13), 7544–7549 (1998).
   PubMed Web of Science ®Google Scholar
• Fenner F, Henderson DA, Arita I, Jazek Z, Ladnyi ID. Smallpox and its eradication. WHO, Geneva, Switzerland, 1–1421 (1988).
   Google Scholar
• Breman JG, Henderson DA. Diagnosis and management of smallpox. N. Engl. J. Med.346(17), 1300–1308 (2002).
   PubMed Web of Science ®Google Scholar
• Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res.58(2), 101–114 (2003).
   PubMed Web of Science ®Google Scholar
• Chen N, Buller RM, Wall EM, Upton C. Analysis of host response modifier ORFs of ectromelia virus, the causative agent of mousepox. Virus Res.66(2), 155–173 (2000).
   PubMed Web of Science ®Google Scholar
• Gubser C, Hue S, Kellam P, Smith GL. Poxvirus genomes: a phylogenetic analysis. J. Gen. Virol.85(Pt 1), 105–117 (2004).
   PubMed Web of Science ®Google Scholar
• McLysaght A, Baldi PF, Gaut BS. Extensive gene gain associated with adaptive evolution of poxviruses. Proc. Natl Acad. Sci. USA100(26), 15655–15660 (2003).
   PubMed Web of Science ®Google Scholar
• Massung RF, Esposito JJ, Liu LI et al. Potential virulence determinants in terminal regions of variola smallpox virus genome. Nature366(6457), 748–751 (1993).
   PubMed Web of Science ®Google Scholar
• Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res.57(1–2), 13–23 (2003).
   PubMed Web of Science ®Google Scholar
• Bras G. The morbid anatomy of smallpox. Doc. Med. Geogr. Trop.4(4), 303–351 (1952).
   PubMedGoogle Scholar
• McKenzie PJ, Githens JH, Harwood ME, Roberts JF, Rao AR, Kempe CH. Haemorrhagic smallpox. 2. Specific bleeding and coagulation studies. Bull. World Health Organ.33(6), 773–782 (1965).
   PubMed Web of Science ®Google Scholar
• Roberts JF, Coffee G, Creel SM et al. Haemorrhagic smallpox. I. Preliminary haematological studies. Bull. World Health Organ.33(5), 607–613 (1965).
   PubMed Web of Science ®Google Scholar
• Esteban DJ, Buller RM. Ectromelia virus: the causative agent of mousepox. J. Gen. Virol.86(Pt 10), 2645–2659 (2005).
   PubMed Web of Science ®Google Scholar
• Johnston JB, McFadden G. Poxvirus immunomodulatory strategies: current perspectives. J. Virol.77(11), 6093 (2003).
   PubMed Web of Science ®Google Scholar
• Born TL, Morrison LA, Esteban DJ et al. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J. Immunol.164(6), 3246–3254 (2000).
   PubMed Web of Science ®Google Scholar
• Reading PC, Smith GL. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J. Virol.77(18), 9960–9968 (2003).
   PubMed Web of Science ®Google Scholar
• Reading PC, Khanna A, Smith GL. Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. Virology292(2), 285–298 (2002).
   PubMed Web of Science ®Google Scholar
• Reading PC, Symons JA, Smith GL. A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. J. Immunol.170(3), 1435–1442 (2003).
   PubMed Web of Science ®Google Scholar
• Bray M, Buller M. Looking back at smallpox. Clin. Infect. Dis.38(6), 882–889 (2004).
   PubMed Web of Science ®Google Scholar
• Martinez MJ, Bray MP, Huggins JW. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch. Pathol. Lab. Med.124(3), 362–377 (2000).
   PubMed Web of Science ®Google Scholar
• Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest.81(12), 1581–1600 (2001).
   PubMed Web of Science ®Google Scholar
• Kim M, Yang H, Kim SK et al. Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J. Biol. Chem.279(24), 25838–25848 (2004).
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Collins DJ, Kern ER. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother.47(10), 3275–3280 (2003).
   PubMed Web of Science ®Google Scholar
• Magee WC, Hostetler KY, Evans DH. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother.49(8), 3153–3162 (2005).
   PubMed Web of Science ®Google Scholar
• Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology318(2), 474–481 (2004).
   PubMed Web of Science ®Google Scholar
• Smee DF, Sidwell RW. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res.57(1–2), 41–52 (2003).
   PubMed Web of Science ®Google Scholar
• Li G, Chen N, Roper RL et al. Complete coding sequences of the rabbitpox virus genome. J. Gen. Virol.86(Pt 11), 2969–2977 (2005).
   PubMed Web of Science ®Google Scholar
• Nelson JB. The behavior of pox viruses in the respiratory tract. J. Exp. Med.68, 401–412 (1938).
   PubMedGoogle Scholar
• De Clercq E, De Somer P. Effect of interferon, polyacrylin acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus. Appl. Microbiol.16(9), 1314–1319 (1968).
   PubMedGoogle Scholar
• Thompson RL, Price M, Minton SA Jr, Falco EA, Hitchings GH. Protection of mice against the vaccinia virus by the administration of phenoxythiouracils. J. Immunol.67(6), 483–491 (1951).
   PubMed Web of Science ®Google Scholar
• Fenner F, Buller RML. Mousepox. In: Viral Pathogenesis. Nathanson N (Ed.), Lippincott-Raven Publishers, PA, USA, 535–553 (1997).
   Google Scholar
• Schriewer J, Buller RM, Owens G. Mouse models for studying orthopoxvirus respiratory infections. Methods Mol. Biol.269, 289–308 (2004).
   PubMedGoogle Scholar
• Mims CA. The response of mice to large intravenous injections of ectromelia virus. I. The fate of injected virus. Br. J. Exp. Pathol.40, 533–542 (1959).
   PubMedGoogle Scholar
• Mims CA. The response of mice to large intravenous injections of ectromelia virus. II. The growth of virus in the liver. Br. J. Exp. Pathol.40, 543–550 (1959).
   PubMed Web of Science ®Google Scholar
• Mims CA. Aspects of the pathogenesis of virus diseases. Bacteriol. Rev.28, 30–71 (1964).
   PubMedGoogle Scholar
• Westwood JC, Boulter EA, Bowen ET, Maber HB. Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br. J. Exp. Pathol.47(5), 453–465 (1966).
   PubMedGoogle Scholar
• Hooper JW, Thompson E, Wilhelmsen C et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol.78(9), 4433–4443 (2004).
   PubMed Web of Science ®Google Scholar
• Huggins JW, Smee DF, Martinez M, Bray M. Cidofovir (HPMPC) treatment of monkeypox. Antiviral Res.37, A37 (1998).
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Hensley LE, Martinez MJ et al. From the cover: exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl Acad. Sci. USA101(42), 15196–15200 (2004).
   PubMed Web of Science ®Google Scholar
• Saraiva M, Smith P, Fallon PG, Alcami A. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J. Exp. Med.196(6), 829–839 (2002).
   PubMed Web of Science ®Google Scholar
• Afonso CL, Tulman ER, Lu Z et al. The genome of camelpox virus. Virology295(1), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Roper RL. Characterization of the vaccinia virus A35R protein and its role in virulence. J. Virol.80(1), 306–313 (2006).
   PubMed Web of Science ®Google Scholar
• Neyts J, Leyssen P, Verbeken E, De CE. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother.48(6), 2267–2273 (2004).
   PubMed Web of Science ®Google Scholar
• Neyts J, Verbeken E, De CE. Effect of 5-iodo-2´-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother.46(9), 2842–2847 (2002).
   PubMed Web of Science ®Google Scholar
• Stittelaar KJ, van AG, Kondova I et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol.79(12), 7845–7851 (2005).
   PubMed Web of Science ®Google Scholar
• LeDuc JW, Jahrling PB. Strengthening national preparedness for smallpox: an update. Emerg. Infect. Dis.7(1), 155–157 (2001).
   PubMed Web of Science ®Google Scholar
• Frey SE, Couch RB, Tacket CO et al. Clinical responses to undiluted and diluted smallpox vaccine. N. Engl. J. Med.346(17), 1265–1274 (2002).
   PubMed Web of Science ®Google Scholar